Roivant Sciences to join BaseLaunch Accelerator as Healthcare Partner
Roivant becomes the fifth healthcare partner of BaselArea.swiss accelerator program joining Johnson & Johnson Innovation, Novartis Venture Fund, Pfizer and Roche.
BaseLaunch Teams (img: Mathias Mangold)
BaseLaunch provides promising startups with access to non-dilutive funding, industry access, expert knowledge and infrastructure, and integrates them into one of the most dynamic biotech and healthcare ecosystems in Europe. The program is initiated and operated by BaselArea.swiss.
In addition to Roivant, the BaseLaunch healthcare accelerator is backed by Johnson & Johnson Innovation, Novartis Venture Fund, Pfizer, Roche and other public and private partners. Sascha Bucher, VP and Head of Global Transactions at Roivant and a senior business development and M&A professional with more than 20 years of experience, will join the BaseLaunch Selection Committee.
For Vivek Ramaswamy, Founder and CEO of Roivant, partnering with BaseLaunch underlines the company’s commitment to Basel as a central hub for pharmaceutical innovation in Europe: “Joining the accelerator will allow us to support young and talented entrepreneurs developing promising ideas, and is representative of our desire to become an integral part of the broader life science ecosystem in Basel.”
Alethia de León, Managing Director of BaseLaunch, welcomes Roivant as a Healthcare Partner of BaseLaunch: “We are very excited to have Roivant as a hands-on partner to support and help select promising healthcare startups. Their commitment to our accelerator here in Basel further adds to the strong commitment to this initiative from the leading and highly innovative corporate partners in the healthcare space.”
“Having the world’s leading healthcare companies onboard demonstrates the unique setting of the Basel region as a center for the life sciences,” says Christof Klöpper, CEO of BaselArea.swiss.
In 2017, over 100 projects applied and 11 teams were accepted into BaseLaunch. During the first three months of the program, company founders worked closely with the BaseLaunch team and a network of seasoned professionals to solidify strategy, R&D plans and operations. The companies that were selected for the next phase will be announced shortly.
Applications for 2018 are now open. For more information, visit www.baselaunch.ch
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More